Nutritional Medicine |
|
|
Clinical Trial: Randomized Trial for Retinitis Pigmentosa
This study is no longer recruiting patients.
|
Purpose
The purpose of this trial is to determine whether a nutritional supplement in addition to vitamin A will slow the course of retinitis pigmentosa.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Retinitis Pigmentosa | Drug: Vitamin A Drug: Nutritional Supplement | Phase III |
MedlinePlus related topics: Eye Diseases; Genetic Disorders; Retinal Disorders
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Study start: May 1996
Retinitis pigmentosa (RP) is a group of inherited retinal degenerations with a worldwide prevalence of approximately 1 in 4,000. Patients typically report night blindness and difficulty with midperipheral visual field in adolescence. As the condition progresses, they lose far peripheral visual field. Most patients have reductions in central vision by age 50 to 80 years. Based on electroretinograms (ERGs), the course of the disease can be slowed on average among adults on 15,000 IU/day of vitamin A palmitate. While conducting the trial on the effects of vitamin A on RP, it became apparent that another substance in the diet could be affecting the course of the disease. This prompted the present randomized, controlled trial.
This study is a randomized, controlled, double-masked trial with a planned duration of 5 years. Patients with the common forms of RP are assigned to either a test or a control group. All receive 15,000 IU/day of vitamin A palmitate in addition to the capsules under study. Participants will not know the contents of the supplement or the group to which they have been assigned until the end of the trial. The main outcome measurement is the total point score on the Humphrey Field Analyzer (HFA). In addition, computer-averaged 30-Hz cone ERG amplitudes and visual acuity are measured annually.
Eligibility
Ages Eligible for Study: 18 Years - 56 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Eligible patients must:
- Be between the ages of 18 and 56
- Be able to see the entire face of someone sitting across the table from them without scanning
- Read newspaper-size print without special magnifying aids
- Walk unaided in daylight
- Have a normal fasting serum vitamin A and normal liver function profile
- Be in good general health
- Reside in the United States
Exclusion Criteria:
- Women who are pregnant or planning to become pregnant cannot be included because of the risk of birth defects that could occur while they are on a vitamin A supplement.
Location Information
Massachusetts
Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, 02114, United States
Eliot Berson, MD, Study Chair, Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School
More Information
Publications that report results of this study
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004 Sep;122(9):1297-305.
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004 Sep;122(9):1306-14.
Record last reviewed: October 2004
Last Updated: October 22, 2004
Record first received: September 23, 1999
ClinicalTrials.gov Identifier: NCT00000116
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


